Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $2.550.00 (0.00%)
Stock chart for: AXSM.O.  Currently trading at $2.55 with a 52 week high of $6.45 and a 52 week low of $2.05.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer

April 19, 2018NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Nick Pizzie, CPA, MBA, as Chief Financial Officer (CFO), effective May 16, 2018. “Nick’s diverse financial experience and expertise make him a strong addition to the Axsome team,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. ... 

Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day

April 11, 2018NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, and Cedric O’Gorman, M.D., Axsome’s Senior Vice President of Clinical Development and Medical Affairs, will participate in the Leerink Partners’ CNS Day on April 18, 2018 at 8:40 AM Eastern Time, in Ne... 

Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence

March 27, 2018NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development (R&D) day with key opinion leaders (KOLs), highlighting the company’s CNS product candidate AXS-05, and unmet needs in depression, agitation associated with Alzheimer’s disease, and nicotine dependence, on Tuesday, ...